317 related articles for article (PubMed ID: 18030030)
1. [Long-term complete remission after single therapy with gemtuzumab ozogamicin for refractory AML in an elderly patient].
Ogura K; Machida T; Nara M; Mayama K; Akagi T; Kubo K
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1881-3. PubMed ID: 18030030
[TBL] [Abstract][Full Text] [Related]
2. Re-administration of a combination of chemotherapy + Gemtuzumab at relapse in CD33+ AML patient allows to second remission and is feasible without extra toxicity.
Chevallier P; Touzeau C; Ayari S; Guillaume T; Harousseau JL; Delaunay J
Leuk Res; 2008 Aug; 32(8):1321-2. PubMed ID: 18029013
[TBL] [Abstract][Full Text] [Related]
3. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
[TBL] [Abstract][Full Text] [Related]
4. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
[TBL] [Abstract][Full Text] [Related]
5. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.
Larson RA; Sievers EL; Stadtmauer EA; Löwenberg B; Estey EH; Dombret H; Theobald M; Voliotis D; Bennett JM; Richie M; Leopold LH; Berger MS; Sherman ML; Loken MR; van Dongen JJ; Bernstein ID; Appelbaum FR
Cancer; 2005 Oct; 104(7):1442-52. PubMed ID: 16116598
[TBL] [Abstract][Full Text] [Related]
6. The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro.
Tanaka M; Kano Y; Akutsu M; Tsunoda S; Izumi T; Yazawa Y; Miyawaki S; Mano H; Furukawa Y
Anticancer Res; 2009 Nov; 29(11):4589-96. PubMed ID: 20032408
[TBL] [Abstract][Full Text] [Related]
7. Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression.
Chevallier P; Mahe B; Garand R; Talmant P; Harousseau JL; Delaunay J
Int J Hematol; 2008 Sep; 88(2):209-211. PubMed ID: 18668307
[TBL] [Abstract][Full Text] [Related]
8. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group.
Taksin AL; Legrand O; Raffoux E; de Revel T; Thomas X; Contentin N; Bouabdallah R; Pautas C; Turlure P; Reman O; Gardin C; Varet B; de Botton S; Pousset F; Farhat H; Chevret S; Dombret H; Castaigne S
Leukemia; 2007 Jan; 21(1):66-71. PubMed ID: 17051246
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment with gemtuzumab ozogamicin monotherapy in a pediatric patient with resistant relapse of acute myeloid leukemia.
Unal S; Cakir M; Kuşkonmaz B; Cetin M; Tuncer AM
Turk J Pediatr; 2009; 51(1):69-71. PubMed ID: 19378895
[TBL] [Abstract][Full Text] [Related]
10. The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells.
ten Cate B; Samplonius DF; Bijma T; de Leij LF; Helfrich W; Bremer E
Leukemia; 2007 Feb; 21(2):248-52. PubMed ID: 17122863
[TBL] [Abstract][Full Text] [Related]
11. [CAG-GO therapy for patients with relapsed or primary refractory CD33-positive acute myelogenous leukemia].
Takahashi W; Nakamura Y; Tadokoro J; Handa T; Arai H; Tokita K; Iso H; Tsurumi S; Sasaki K; Maki K; Mitani K
Rinsho Ketsueki; 2012 Jan; 53(1):71-7. PubMed ID: 22374527
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic advances in neoplastic hematology: target therapy anti-CD33].
Di Rocco A; Finolezzi E; Anaclerico B; Calabrese E; Levi A; Trasarti S; Tafuri A
Clin Ter; 2005; 156(4):183-6. PubMed ID: 16342520
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study.
Kobayashi Y; Tobinai K; Takeshita A; Naito K; Asai O; Dobashi N; Furusawa S; Saito K; Mitani K; Morishima Y; Ogura M; Yoshiba F; Hotta T; Bessho M; Matsuda S; Takeuchi J; Miyawaki S; Naoe T; Usui N; Ohno R
Int J Hematol; 2009 May; 89(4):460-469. PubMed ID: 19360457
[TBL] [Abstract][Full Text] [Related]
14. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
Chevallier P; Delaunay J; Turlure P; Pigneux A; Hunault M; Garand R; Guillaume T; Avet-Loiseau H; Dmytruk N; Girault S; Milpied N; Ifrah N; Mohty M; Harousseau JL
J Clin Oncol; 2008 Nov; 26(32):5192-7. PubMed ID: 18854573
[TBL] [Abstract][Full Text] [Related]
15. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.
Linenberger ML
Leukemia; 2005 Feb; 19(2):176-82. PubMed ID: 15592433
[TBL] [Abstract][Full Text] [Related]
16. Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin.
Duong HK; Sekeres MA
Clin Interv Aging; 2009; 4():197-205. PubMed ID: 19503782
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk.
Balaian L; Ball ED
Leukemia; 2006 Dec; 20(12):2093-101. PubMed ID: 17051243
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and toxicity of gemtuzumab ozogamicin in patients with acute myeloid leukemia.
van der Heiden PL; Jedema I; Willemze R; Barge RM
Eur J Haematol; 2006 May; 76(5):409-13. PubMed ID: 16480432
[TBL] [Abstract][Full Text] [Related]
19. What role does gemtuzumab ozogamicin have in the treatment of acute myelogenous leukemia?
Molnár I; Powell BL
Curr Hematol Malig Rep; 2007 May; 2(2):104-10. PubMed ID: 20425358
[TBL] [Abstract][Full Text] [Related]
20. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.
Pollard JA; Alonzo TA; Loken M; Gerbing RB; Ho PA; Bernstein ID; Raimondi SC; Hirsch B; Franklin J; Walter RB; Gamis A; Meshinchi S
Blood; 2012 Apr; 119(16):3705-11. PubMed ID: 22378848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]